Thiothixene is metabolized in the liver and is excreted mainly in feces via biliary elimination as unchanged drug and as the demethyl, sulfoxide, demethylated sulfoxide, and hydroxylated thiothixene derivatives.
IDENTIFICATION AND USE: Thiothixene is a solid. It is antipsychotic agent and dopamine antagonist. Thiothixene capsules are effective in the management of schizophrenia. HUMAN STUDIES: Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs, including thiothixene. A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including thiothixene. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Manifestations of overdose include muscular twitching, drowsiness and dizziness. Symptoms of gross overdosage may include CNS depression, rigidity, weakness, torticollis, tremor, salivation, dysphagia, hypotension, disturbances of gait, or coma. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Thiothixene may be additive with or may potentiate the action of other CNS depressants (including alcohol), anticholinergics, or hypotensive agents. ANIMAL STUDIES: In animal reproduction studies with thiothixene, there was some decrease in conception rate and litter size, and an increase in resorption rate in rats and rabbits. After repeated oral administration of thiothixene to rats (5 to 15 mg/kg/day), rabbits (3 to 50 mg/kg/day), and monkeys (1 to 3 mg/kg/day) before and during gestation, no teratogenic effects were seen.
◉ Summary of Use during Lactation:Because there is no published experience with thiothixene during breastfeeding, other antipsychotic agents are preferred.
◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk:Thiothixene has caused galactorrhea. Hyperprolactinemia appears to be the cause of the galactorrhea. The hyperprolactinemia is caused by the drug's dopamine-blocking action in the tuberoinfundibular pathway. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed for signs of reduced thiothixene effectiveness.
In this study healthy volunteers received thiothixene with and without a 3-day pretreatment with paroxetine to determine if paroxetine decreased the clearance of thiothixene. Ten healthy medication-free volunteers (4 women and 6 men, mean age 38 +/- 12 years) were randomized to receive a single 20 mg oral dose of thiothixene on two separate occasions. On one occasion thiothixene was given concurrently, and following 3 days of pre-treatment with oral paroxetine (20 mg/day). On the other occasion thiothixene was given without paroxetine pre-treatment. The two study days were separated by a minimum period of 2 weeks. On both study days, after the administration of thiothixene, 10 mL blood samples were collected over the next 72 hr. None of the pharmacokinetic parameters of thiothixene were significantly altered by a 3-day treatment with paroxetine. It is likely that the CYP2D6 isoenzyme is not responsible for a high proportion of thiothixene clearance, but one cannot exclude the possibility that a longer paroxetine pretreatment might have caused some inhibition of thiothixene clearance.
Fifty-nine plasma thiothixene concentrations were measured in 42 patients as part of routine therapeutic drug monitoring. Data collection included concomitant medications, smoking history, and demographic variables. A retrospective analysis was performed to assess the effect of these parameters on oral thiothixene clearance. When groups of patients were categorized by concomitant medications (i.e., no interacting drugs, enzyme/clearance inducers, and enzyme/clearance inhibitors), thiothixene clearance was found to be significantly increased by enzyme inducing drugs (e.g., anticonvulsants) and decreased by clearance inhibiting agents (e.g., cimetidine). Tobacco smoking significantly increased the hepatic clearance of thiothixene within the no interactions and inhibitor groups, but not in the inducer group. Significantly more patients in the inducer group had nondetectable plasma concentrations of thiothixene than the other groups. When the entire patient population was dichotomized by age, patients less than 50 years old had a significantly greater mean clearance (48.2 +/- 37.8 liters/min) versus those greater than or equal to 50 (20.0 +/- 12.6 liters/min). Men in this cohort exhibited a significantly higher clearance (49.2 +/- 38.7 liters/min) than did the women (22.0 +/- 13.5 liters/min). By taking into account these potential sources of pharmacokinetic variability when monitoring plasma thiothixene concentrations, more appropriate dosing of thiothixene may be achieved. Controlled, prospective studies are needed to validate these findings.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
硫替噻嗪在体内分布广泛，给药后可能在体内停留数周。
Thiothixene is widely distributed into body tissues and may remain in the body for several weeks following administration.
Thiothixene is well absorbed from the GI tract. Therapeutic response may occur within a few days to several weeks following oral administration of the drug. Plasma concentrations required for therapeutic effects are not known.
Two experiments are reported in which acute single test dose levels of thiothixene (Navane) were correlated with age. In the first study 20 mg oral doses were given to 28 male subjects and serum levels were drawn 2 hr later. Mean age was 30 and correlation of serum level with age was 0.43, P less than 0.02. In a second older group with a mean age of 41, 10 mg oral doses were given to 25 subjects. A correlation with age of 0.41, P less than 0.05 was obtained with age. In prior work such acute levels have been found to correlate with steady-state serum levels and with clinical response to the medication. ...
Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds
申请人：——
公开号：US20020010198A1
公开（公告）日：2002-01-24
Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.
Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.
[EN] METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS<br/>[FR] PROCEDES D'UTILISATION D'INHIBITEURS DE RECAPTAGE DE LA DOPAMINE ET COMPOSITIONS CONTENANT CES DERNIERS
申请人：SEPRACOR INC
公开号：WO2000010551A2
公开（公告）日：2000-03-02
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites like desmethylsibutramine and didesmethylsibutramine and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3, antagonists.
Compositions comprising dopamine reuptake inhibitors and methods of making and using the same
申请人：Sepracor Inc.
公开号：US20020183281A1
公开（公告）日：2002-12-05
Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
Methods of treating or preventing restless leg syndrome using sibutramine metabolites
申请人：——
公开号：US20040067957A1
公开（公告）日：2004-04-08
Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.
Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.
Methods of treating or preventing weight gain, obesity, and related disorders
申请人：Sepracor Inc.
公开号：US20020188029A1
公开（公告）日：2002-12-12
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT
3
antagonists.
![(E)-N,N-二甲基-9-[3-(4-甲基-1-哌嗪基)亚丙基]-9H-硫蒽-2-磺酰胺化学式](data:image/svg+xml;base64,<?xml version="1.0" encoding="UTF-8"?>
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" width="300" height="300" viewBox="0 0 300 300">
<defs>
<g>
<g id="glyph-0-0">
<path d="M 0.5 1.765625 L 0.5 -7.0625 L 5.5 -7.0625 L 5.5 1.765625 Z M 1.0625 1.21875 L 4.953125 1.21875 L 4.953125 -6.5 L 1.0625 -6.5 Z M 1.0625 1.21875 "/>
</g>
<g id="glyph-0-1">
<path d="M 5.359375 -7.0625 L 5.359375 -6.09375 C 4.984375 -6.28125 4.628906 -6.414062 4.296875 -6.5 C 3.960938 -6.582031 3.640625 -6.625 3.328125 -6.625 C 2.796875 -6.625 2.382812 -6.519531 2.09375 -6.3125 C 1.800781 -6.101562 1.65625 -5.804688 1.65625 -5.421875 C 1.65625 -5.097656 1.75 -4.851562 1.9375 -4.6875 C 2.132812 -4.53125 2.503906 -4.398438 3.046875 -4.296875 L 3.640625 -4.171875 C 4.378906 -4.035156 4.921875 -3.789062 5.265625 -3.4375 C 5.617188 -3.082031 5.796875 -2.609375 5.796875 -2.015625 C 5.796875 -1.304688 5.554688 -0.769531 5.078125 -0.40625 C 4.609375 -0.0390625 3.914062 0.140625 3 0.140625 C 2.65625 0.140625 2.285156 0.0976562 1.890625 0.015625 C 1.503906 -0.0546875 1.101562 -0.171875 0.6875 -0.328125 L 0.6875 -1.34375 C 1.09375 -1.113281 1.484375 -0.941406 1.859375 -0.828125 C 2.242188 -0.710938 2.625 -0.65625 3 -0.65625 C 3.5625 -0.65625 3.992188 -0.765625 4.296875 -0.984375 C 4.609375 -1.210938 4.765625 -1.53125 4.765625 -1.9375 C 4.765625 -2.300781 4.65625 -2.582031 4.4375 -2.78125 C 4.21875 -2.976562 3.859375 -3.128906 3.359375 -3.234375 L 2.75 -3.359375 C 2.007812 -3.503906 1.472656 -3.734375 1.140625 -4.046875 C 0.816406 -4.359375 0.65625 -4.789062 0.65625 -5.34375 C 0.65625 -5.988281 0.882812 -6.5 1.34375 -6.875 C 1.800781 -7.25 2.425781 -7.4375 3.21875 -7.4375 C 3.5625 -7.4375 3.910156 -7.40625 4.265625 -7.34375 C 4.617188 -7.28125 4.984375 -7.1875 5.359375 -7.0625 Z M 5.359375 -7.0625 "/>
</g>
<g id="glyph-0-2">
<path d="M 0.984375 -7.296875 L 2.3125 -7.296875 L 5.546875 -1.1875 L 5.546875 -7.296875 L 6.515625 -7.296875 L 6.515625 0 L 5.171875 0 L 1.9375 -6.109375 L 1.9375 0 L 0.984375 0 Z M 0.984375 -7.296875 "/>
</g>
<g id="glyph-0-3">
<path d="M 3.953125 -6.625 C 3.234375 -6.625 2.660156 -6.359375 2.234375 -5.828125 C 1.816406 -5.296875 1.609375 -4.566406 1.609375 -3.640625 C 1.609375 -2.722656 1.816406 -1.992188 2.234375 -1.453125 C 2.660156 -0.921875 3.234375 -0.65625 3.953125 -0.65625 C 4.660156 -0.65625 5.222656 -0.921875 5.640625 -1.453125 C 6.066406 -1.992188 6.28125 -2.722656 6.28125 -3.640625 C 6.28125 -4.566406 6.066406 -5.296875 5.640625 -5.828125 C 5.222656 -6.359375 4.660156 -6.625 3.953125 -6.625 Z M 3.953125 -7.4375 C 4.972656 -7.4375 5.789062 -7.09375 6.40625 -6.40625 C 7.019531 -5.71875 7.328125 -4.796875 7.328125 -3.640625 C 7.328125 -2.492188 7.019531 -1.578125 6.40625 -0.890625 C 5.789062 -0.203125 4.972656 0.140625 3.953125 0.140625 C 2.921875 0.140625 2.097656 -0.195312 1.484375 -0.875 C 0.867188 -1.5625 0.5625 -2.484375 0.5625 -3.640625 C 0.5625 -4.796875 0.867188 -5.71875 1.484375 -6.40625 C 2.097656 -7.09375 2.921875 -7.4375 3.953125 -7.4375 Z M 3.953125 -7.4375 "/>
</g>
<g id="glyph-0-4">
<path d="M 6.453125 -6.734375 L 6.453125 -5.703125 C 6.117188 -6.003906 5.765625 -6.234375 5.390625 -6.390625 C 5.015625 -6.546875 4.613281 -6.625 4.1875 -6.625 C 3.351562 -6.625 2.710938 -6.367188 2.265625 -5.859375 C 1.828125 -5.347656 1.609375 -4.609375 1.609375 -3.640625 C 1.609375 -2.679688 1.828125 -1.945312 2.265625 -1.4375 C 2.710938 -0.925781 3.351562 -0.671875 4.1875 -0.671875 C 4.613281 -0.671875 5.015625 -0.742188 5.390625 -0.890625 C 5.765625 -1.046875 6.117188 -1.28125 6.453125 -1.59375 L 6.453125 -0.5625 C 6.109375 -0.320312 5.738281 -0.144531 5.34375 -0.03125 C 4.957031 0.0820312 4.550781 0.140625 4.125 0.140625 C 3.019531 0.140625 2.148438 -0.195312 1.515625 -0.875 C 0.878906 -1.550781 0.5625 -2.472656 0.5625 -3.640625 C 0.5625 -4.816406 0.878906 -5.742188 1.515625 -6.421875 C 2.148438 -7.097656 3.019531 -7.4375 4.125 -7.4375 C 4.5625 -7.4375 4.972656 -7.378906 5.359375 -7.265625 C 5.742188 -7.148438 6.109375 -6.972656 6.453125 -6.734375 Z M 6.453125 -6.734375 "/>
</g>
<g id="glyph-0-5">
<path d="M 0.984375 -7.296875 L 1.96875 -7.296875 L 1.96875 -4.3125 L 5.5625 -4.3125 L 5.5625 -7.296875 L 6.546875 -7.296875 L 6.546875 0 L 5.5625 0 L 5.5625 -3.484375 L 1.96875 -3.484375 L 1.96875 0 L 0.984375 0 Z M 0.984375 -7.296875 "/>
</g>
<g id="glyph-1-0">
<path d="M 0.328125 1.171875 L 0.328125 -4.703125 L 3.671875 -4.703125 L 3.671875 1.171875 Z M 0.703125 0.8125 L 3.296875 0.8125 L 3.296875 -4.328125 L 0.703125 -4.328125 Z M 0.703125 0.8125 "/>
</g>
<g id="glyph-1-1">
<path d="M 2.703125 -2.625 C 3.015625 -2.550781 3.257812 -2.410156 3.4375 -2.203125 C 3.613281 -1.992188 3.703125 -1.726562 3.703125 -1.40625 C 3.703125 -0.925781 3.535156 -0.554688 3.203125 -0.296875 C 2.878906 -0.0351562 2.414062 0.09375 1.8125 0.09375 C 1.601562 0.09375 1.390625 0.0703125 1.171875 0.03125 C 0.960938 -0.0078125 0.742188 -0.0664062 0.515625 -0.140625 L 0.515625 -0.78125 C 0.691406 -0.675781 0.890625 -0.59375 1.109375 -0.53125 C 1.328125 -0.476562 1.550781 -0.453125 1.78125 -0.453125 C 2.195312 -0.453125 2.515625 -0.535156 2.734375 -0.703125 C 2.953125 -0.867188 3.0625 -1.101562 3.0625 -1.40625 C 3.0625 -1.695312 2.957031 -1.921875 2.75 -2.078125 C 2.550781 -2.242188 2.273438 -2.328125 1.921875 -2.328125 L 1.34375 -2.328125 L 1.34375 -2.875 L 1.9375 -2.875 C 2.257812 -2.875 2.503906 -2.9375 2.671875 -3.0625 C 2.847656 -3.1875 2.9375 -3.375 2.9375 -3.625 C 2.9375 -3.875 2.847656 -4.0625 2.671875 -4.1875 C 2.492188 -4.320312 2.242188 -4.390625 1.921875 -4.390625 C 1.734375 -4.390625 1.535156 -4.367188 1.328125 -4.328125 C 1.128906 -4.296875 0.90625 -4.238281 0.65625 -4.15625 L 0.65625 -4.75 C 0.90625 -4.8125 1.140625 -4.859375 1.359375 -4.890625 C 1.578125 -4.929688 1.78125 -4.953125 1.96875 -4.953125 C 2.46875 -4.953125 2.863281 -4.835938 3.15625 -4.609375 C 3.445312 -4.378906 3.59375 -4.070312 3.59375 -3.6875 C 3.59375 -3.414062 3.515625 -3.1875 3.359375 -3 C 3.210938 -2.820312 2.992188 -2.695312 2.703125 -2.625 Z M 2.703125 -2.625 "/>
</g>
</g>
</defs>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.66232 2.671091 L 4.68166 2.671091 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.671842 2.671091 L 3.172007 3.53714 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.479526 2.671091 L 3.075849 3.370424 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.676682 2.679365 L 3.167168 1.796769 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 4.667142 2.662818 L 5.176812 3.545413 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 4.671982 2.671091 L 5.176812 1.796769 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 4.864454 2.671091 L 5.273127 1.963485 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.167168 3.52871 L 3.517771 4.136255 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.181685 3.53714 L 2.162346 3.53714 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.181685 1.805043 L 2.172024 1.805043 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.085371 1.971759 L 2.268182 1.971759 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 5.172129 3.53714 L 4.671982 4.403032 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 5.268287 3.703699 L 4.864454 4.403032 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 5.162451 3.53714 L 6.181634 3.53714 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 5.162451 1.805043 L 6.181634 1.805043 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 3.884608 4.403032 L 4.68166 4.403032 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 2.176863 3.545413 L 1.667193 2.662818 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 2.273021 3.378697 L 1.859666 2.662818 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 2.176863 1.796769 L 1.667193 2.679365 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 2.176863 1.813472 L 1.826104 1.205927 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 4.667142 4.394759 L 5.176812 5.277354 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 6.167117 3.52871 L 6.676943 4.411461 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 6.070959 3.695426 L 6.48447 4.411461 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 6.167117 1.813472 L 6.676943 0.930721 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 1.435695 1.002527 L 0.950065 1.132716 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 1.962068 0.896067 L 2.332808 0.723575 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 1.891666 0.744961 L 2.262562 0.572469 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 1.647837 0.629134 L 1.514526 0.263233 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 1.491267 0.686267 L 1.357957 0.320366 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 5.162451 5.26908 L 6.181634 5.26908 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 5.258609 5.102364 L 6.08532 5.102364 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 6.676943 4.394759 L 6.167117 5.277354 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 6.662426 0.93915 L 7.451672 0.93915 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 0.487694 0.979425 L 0.22482 0.716082 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 0.631463 1.477387 L 0.524066 1.879191 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 7.82569 0.672998 L 8.176918 0.0646726 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 7.82569 1.205303 L 8.176918 1.813472 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 8.1624 0.0729459 L 9.18174 0.0729459 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 8.1624 1.805043 L 9.18174 1.805043 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 9.167379 0.0646726 L 9.519074 0.672998 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 9.167379 1.813472 L 9.519074 1.205147 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<path fill="none" stroke-width="0.0333333" stroke-linecap="butt" stroke-linejoin="miter" stroke="rgb(0%, 0%, 0%)" stroke-opacity="1" stroke-miterlimit="10" d="M 9.893248 0.93915 L 10.445534 0.93915 " transform="matrix(25.023861, 0, 0, 25.023861, 16.460076, 86.299611)"/>
<g fill="rgb(65.677643%, 50.224078%, 7.726782%)" fill-opacity="1">
<use xlink:href="#glyph-0-1" x="105.117188" y="200.125"/>
</g>
<g fill="rgb(65.677643%, 50.224078%, 7.726782%)" fill-opacity="1">
<use xlink:href="#glyph-0-1" x="55.074219" y="113.441406"/>
</g>
<g fill="rgb(19%, 31%, 97.000003%)" fill-opacity="1">
<use xlink:href="#glyph-0-2" x="30.386719" y="119.933594"/>
</g>
<g fill="rgb(100%, 5.1%, 5.1%)" fill-opacity="1">
<use xlink:href="#glyph-0-3" x="77.0625" y="102.882813"/>
</g>
<g fill="rgb(100%, 5.1%, 5.1%)" fill-opacity="1">
<use xlink:href="#glyph-0-3" x="45.804688" y="89.941406"/>
</g>
<g fill="rgb(19%, 31%, 97.000003%)" fill-opacity="1">
<use xlink:href="#glyph-0-2" x="204.699219" y="113.449219"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-0-4" x="12.957031" y="102.226563"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-0-5" x="2.101562" y="102.097656"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-1-1" x="8.96875" y="102.671875"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-0-4" x="24.167969" y="144.09375"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-0-5" x="30.464844" y="143.964844"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-1-1" x="37.332031" y="144.539062"/>
</g>
<g fill="rgb(19%, 31%, 97.000003%)" fill-opacity="1">
<use xlink:href="#glyph-0-2" x="254.769531" y="113.449219"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-0-4" x="280.039062" y="113.441406"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-0-5" x="286.335938" y="113.3125"/>
</g>
<g fill="rgb(0%, 0%, 0%)" fill-opacity="1">
<use xlink:href="#glyph-1-1" x="293.203125" y="113.882813"/>
</g>
</svg>
)
